Document is current

Article History

Received: 29 June 2024

Accepted: 12 August 2024

First Online: 16 September 2024

Declarations

:

: Andrew Blauvelt: Has served as a speaker (received honoraria) for Eli Lilly and Company and UCB Pharma, served as a scientific adviser (received honoraria) for AbbVie, Abcentra, Aclaris, Affibody, Aligos, Almirall, Alumis, Amgen, Anaptysbio, Apogee, Arcutis, Arena, Aslan, Athenex, Bluefin Biomedicine, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Celldex, CTI BioPharma, Dermavant Sciences, EcoR1, Eli Lilly and Company, Escient, Evelo, Evommune, Forte, Galderma, HighlightII Pharma, Incyte, InnoventBio, Janssen, Landos, LEO Pharma, Lipidio, Merck, Microbion, Monte Rosa Therapeutics, Nektar, Novartis, Overtone Therapeutics, Paragon, Pfizer, Q32 Bio, Rani, Rapt, Regeneron, Sanofi, Spherix Global Insights, Sun Pharma, Takeda, TLL Pharmaceutical, TrialSpark, UCB Pharma, Union, Ventyx, Vibliome, and Xencor, and has acted as a clinical study investigator (institution has received clinical study funds) for AbbVie, Acelyrin, Allakos, Almirall, Alumis, Amgen, Arcutis, Athenex, Boehringer Ingelheim, Bristol Myers Squibb, Concert, Dermavant Sciences, DermBiont, Eli Lilly and Company, Evelo, Evommune, Galderma, Incyte, Janssen, LEO Pharma, Merck, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharma, UCB Pharma, and Ventyx, and owns stock in Lipidio and Oruka; Robert R. McLean, Adam P. Sima: Employees of CorEvitas, LLC; Silky W. Beaty: Employee at the time of the research and current shareholder of UCB Pharma; Robert Low, Jeffrey L. Stark, Laura McClung: Employees and shareholders of UCB Pharma; Jerry Bagel: Has received research funds payable to Psoriasis Treatment Center from AbbVie, Amgen, Arcutis Biotherapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, CorEvitas, LLC, Dermavant Sciences, LTD, Dermira, UCB Pharma, Eli Lilly and Company, Glenmark Pharmaceuticals, Janssen, Kadmon Corporation, LEO Pharma, Lycera Corp, Menlo Therapeutics, Novartis, Pfizer, Regeneron, Sun Pharma, Taro Pharmaceutical Industries Ltd., and Ortho Dermatologics; consultant fees from AbbVie, Amgen, Celgene, Bristol Myers Squibb, Eli Lilly and Company, Janssen, Novartis, Sun Pharma, UCB Pharma, and fees for speaking from AbbVie, Celgene, Eli Lilly and Company, Janssen, and Novartis.

: This study was performed in accordance with the Declaration of Helsinki and the Guidelines for Good Pharmacoepidemiology Practice []. All participating investigators were required to obtain full board approval for conducting noninterventional research involving human subjects with a limited dataset. Sponsor approval and continuing review were obtained through a central Institutional Review Board (IRB), (Advarra, Protocol number Pro00051221). For academic investigative sites that did not receive authorization to use the central IRB, full board approval was obtained from their respective governing IRBs, and documentation of approval was submitted to CorEvitas, LLC, before the site’s participation and initiation of any study procedures. All patients in the registry were required to provide written informed consent and authorization before participating in the CorEvitas Psoriasis Registry.